Women with a pelvic mass: Indicators of malignancy

Objective: To evaluate the efficacy of five methods: pelvic examination (PE), transvaginal ultrasonography (US), Doppler ultrasonography, serum CA125 assay and serum CA72-4 assay, alone or associated, to predict malignancy in patients presenting a pelvic mass originating in the ovary.

Methods: 92 patients underwent a standard protocol for physical examination, CA125, CA72-4, transvaginal ultrasonography and Doppler ultrasonography.

Results: Eighteen women were dropped from the study because they had clearly benign masses; two women were dropped from the study because they had clearly malignant lesions. Twenty-two malignant (30%) and 50 benign (70%) pelvic tumors were found. When one method was considered alone the best sensitivity (SENS) was found in physical examination (90%) and the best specificity (SPEC) was found in CA72-4: 88%. If all indicators were positive, the SPEC was 100% but the SENS was 40%. Logistic regression analysis prediction of the character of the pelvic masses was correct in 86%.

Conclusion: Some additional information to discriminate between malignant and benign pelvic masses can be obtained from the valuation of serum tumor markers, particularly CA72-4. Also Doppler ultrasonography appeared to be useful in the differential diagnosis of pelvic tumors. The prediction of the character of the pelvic masses calculated by a logistic model in which PE, US, CA 125, and CA72-4 are included is very good.

Pelvic mass; Pelvic examination; Ultrasonography; Doppler ultrasonography; CA125; CA72-4

[1] Klug T., Bast R., Niloff J., Knapp R., Zurawki V.: "A monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with uman epithelial ovarian carcinomas". Cancer Res., 1984, 44, 1048.

[2] Bast R., Klug T., St John E., Niloff J., Lazarus H., Bercowitz R., Leavitt T. et al.: "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". N. Engl. J. Med., 1983, 309, 883.

[3] Jacobs L., Bast R.: "The CA125 tumor associated antigen: a review of the literature". Hum. Reprod., 1989, 4, 1.

[4] Kenemans P.,Y edema C. A.,B on C. G.,v on Mensdorff-Pouilly S.: "CA125 in gynecological pathology-a review". Eur. J. Obstet. Gynecol. Reprod. Biol., 1993, 49, 115.

[5] Nutti M., Teramoto Y. A., Mariani-Constanti R., Horan Hand P., Colcher D., Scholm J.: "A monoclonal antibody (B 72-3) defines pattern of distribution of a novel tumor-associated antigen in Human mammary cell population". Int. J. Cancer, 1982, 29, 539.

[6] Thor A., Ohuchi N., Szpak C. A., Johnston W.W., Scholm J.: "Distribution of oncofetal antigen tumor associated glycoprotein-72 defined by monoclonal antibody B 72-3". Cancer Res., 1986, 46, 3118.

[7] Paterson A. J., Schlom J., Sears H.F.: "A radioimmunoassay for the detection of a human tumor associated glycoprotein (TAG-72) using monoclonal antibody B 72-3". Int. J. Cancer, 1986, 37, 659.

[8] Wu J. T., Carlisle P.: "Low frequency and low level of elevation of serum CA72-4 in human carcinomas in comparison with established tumor markers". J. Clin. Lab. Anal., 1992, 6, 59.

[9] Gaducci A., Ferdeghini M., Prontera C., Moretti L., Mariani G., Bianchi R., Fioretti P.: "The concomitant determination of different serum tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis". Gynecol. Oneal., 1992, 44, 147.

[10] Maggino T., Gadducci A., D'Addrio V., Pecorelli S.: "Prospective multicenter study on the clinical utility of CA 72-4 in postrnenopausal patients with pelvic mass". Oneal. Rep., 1995, 2, 1069.

[11] Granberg S., Norstrom A., Wikland M.: "Tumors in the lower pelvis as imaged by vaginal sonography". Gynecol. Oneal., 1990, 37, 224.

[12] Kurjak A., Zalud I., Alfrievic Z.: "E valuation of adenaxal masses with transvaginal colour ultrasound". J. Ultrasound Med., 1991, 10, 295.

[13] Bourne T., Campbell S., Steer C., Whitehead M. I., Collins W. P.: "Transvaginal color flow imaging: a possible new screening technique for ovarian cancer". Br. Med. J., 1989, 299, 1367.

[14] Kawai M., Kano T., Kikkawa F., Maeda 0., Oguchi H., Tomoda Y.: "Transvaginal color flow imaging in the diagnosis of ovarian cancer". Obstet. Gynecol., 1992, 79, 163.

[15] Weiner Z.,T haler I.,B eck D.,R ottem S.,D eutsch M.,B randes J.: "Differentiating malignant from benign ovarian tumors with transvaginal colour flow imaging". Obstet. Gynecol., 1992, 79, 159.

[16] Hata K., Hata T., Kitao M.: "Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy". Am. J. Obstet. Gynecol., 1995, 172, 1496.

[17] Tailor A., Jurkovic D.,B ourne T. H., Natucci M., Collins W. P., Campbell S.: "A comparation of intratumoral indices of blood flow velocity and impedance for the diagnosis of ovarian cancer". Ultrasound Med. Biol., 1996, 22, 837.

[18] Tekay A., Jouppila P.: "Blood flow in benign ovarian tumors and normal ovaries during the follicular phase". Obstet. Gynecol., 1995, 86, 55.

[19] Valentin L., Sladkevicius P., Marsal K.: "Limited contribution of Doppler veloclmetry to the differential dlagnosIS of extrauterme pelvic tumors". Obstet. Gynecol., 1994, 83, 425.

[20] Thompson R. S., Trudinger B. J., Cook C. M.: "Doppler ultrasound waveform indices: A/B ratio, pulsatility index and Pourcelot ratio". Br. J. Obstet. Gynaecol., 1998, 95, 581.

[21] Serov S. F., Scully R. E., Sobin L. H.: "International Histological Classification of Tumors". No. 9 Histological Typing of Ovarian Tumors. Geneva, World Healt Organization, 1973.

[22] Schutter E. M. J., Kenemans P., Sohn C.,K risten P.,C rombach G., Westerman R., Mobus V. et al.: "Diagnostic value of pelvic examination, ultrasound and serum CA125 in postmenopausal women presenting with a pelvic mass, an international multicenter study". Cancer, 1994, 74, 1398.

[23] Buist M. R., Golding R. P.,B ulger C. W.,V ermorken J.B., Kenemans P.: "Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI". Gynecol. Oneal., 1994, 52, 191.

[24] Finkler N. J.,B enacerrafB.,L avin P. T.,W ojciechowski C.,K napp R. C.: "Comparation of serum CA125, clinical impression, and ultrasound in the preoperative evaluation of pelvic masses". Obstet. Gynecol., 1988, 72, 659.

[25] O'Connel G., Ryan E., Murphy J., Prefontaine M. M.: "Predictive value of CA125 for ovarian carcinoma in patients presenting with pelvic masses". Obstet. Gynecol., 1987, 70, 930.

[26] Vasilev S. A., Schlaeth J. B., Campeau J., Morrow Cp.: "Serum CA 125 levels in preoperative evaluation of pelvic masses". Obstet. Gynecol., 1988, 71, 751.

[27] Malkasian G. D., Knapp R. C., Lavin P. T., Zurawski Vr., Podraz K. C., Stanhope C. R. et al.: "Preoperative evaluation of serum CA125 levels in premenopausal and postmenopausal patients with pelvic masses: cliscrimination of benign from malignant disease". Am. J. Obstet. Gynecol., 1988, 159, 341.

[28] Gramberg S., Norstrom A., Wikland M.: "Tumors in the lower pelvis as imaged by vaginal sonography". Gynecol. Oneal., 1990, 37, 224.

[29] Folkman J.: "Tumor angiogenesis: Therapeutic implications". N. Engl. J. Med., 1971, 285, 1182.

[30] Folkman J., Merler E., Agernathy C., Williams G.: "Isolation of a tumor factor responsible for angiogenesis". J. Exp. Med., 1971, 33, 275.

[31] Reynolds K., Farzaneh F., Collins W. P., Campbell S.: "Assoc1ation of ovarian malignancy with expression of plateled-derived endothelial cell growth factor". J. Natl. Cancer Inst., 1994, 86, 1234.